INS and type 1 diabetes mellitus: ADJUNCT‐ONE and ADJUNCT‐TWO were key randomised controlled phase 3 trials in 1398 and 835 participants with T1D treated with liraglutide (0.6, 1.2 or 1.8 mg) or placebo, all as adjuncts to insulin.